{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:42:01Z","timestamp":1793522521590,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00210-022-02375-4","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T07:10:11Z","timestamp":1672816211000},"page":"1031-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Novel combination treatment of CDK 4\/6 inhibitors with PARP inhibitors in triple negative breast cancer cells"],"prefix":"10.1007","volume":"396","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-9914","authenticated-orcid":false,"given":"Gamze","family":"Guney Eskiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Ozman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten","family":"Haciefendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demet","family":"Cansaran-Duman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"2","key":"2375_CR1","doi-asserted-by":"publisher","first-page":"100995","DOI":"10.1016\/j.tranon.2020.100995","volume":"14","author":"Z Albakova","year":"2021","unstructured":"Albakova Z, Siam MKS, Sacitharan PK, Ziganshin RH, Ryazantsev DY, Sapozhnikov AM (2021) Extracellular heat shock proteins and cancer: new perspectives. Transl Oncol 14(2):100995","journal-title":"Transl Oncol"},{"issue":"11","key":"2375_CR2","first-page":"1123","volume":"14","author":"JRE Choo","year":"2018","unstructured":"Choo JRE, Lee SC (2018) CDK4\u20136 inhibitors in breast cancer: current status and future development. Expert Opin Drug Metab Toxicol 14(11):1123\u20131138","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"2375_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681","journal-title":"Pharmacol Rev"},{"issue":"2","key":"2375_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10549-012-2106-5","volume":"134","author":"HC Chuang","year":"2012","unstructured":"Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL (2012) Differential anti-proliferative activities of poly (ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 134(2):649\u2013659","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2375_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","volume":"9","author":"JM Collins","year":"2021","unstructured":"Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM (2021) A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status. Oncol Ther 9(2):575\u2013589","journal-title":"Oncol Ther"},{"key":"2375_CR6","doi-asserted-by":"publisher","unstructured":"Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Targeted oncology 16(3):255\u2013282. https:\/\/doi.org\/10.1007\/s11523-021-00796-4","DOI":"10.1007\/s11523-021-00796-4"},{"issue":"1","key":"2375_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-49484-4","volume":"9","author":"D Cretella","year":"2019","unstructured":"Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG (2019) Pre-treatment with the CDK4\/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Sci Rep 9(1):1\u201311","journal-title":"Sci Rep"},{"issue":"11","key":"2375_CR8","first-page":"1","volume":"35","author":"GG Eskiler","year":"2018","unstructured":"Eskiler GG, Cecener G, Egeli U, Tunca B (2018) Synthetically lethal BMN 673 (talazoparib) loaded solid lipid nanoparticles for BRCA1 mutant triple negative breast cancer. Pharm Res 35(11):1\u201320","journal-title":"Pharm Res"},{"key":"2375_CR9","doi-asserted-by":"crossref","unstructured":"Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, ... and Sicinski P (2020) Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4\/6 inhibition. Sci Adv 6(25):eabb2210","DOI":"10.1126\/sciadv.abb2210"},{"issue":"9","key":"2375_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/gb-2003-4-9-117","volume":"4","author":"D Greenbaum","year":"2003","unstructured":"Greenbaum D, Colangelo C, Williams K, Gerstein M (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4(9):117","journal-title":"Genome Biol"},{"key":"2375_CR11","doi-asserted-by":"crossref","unstructured":"Guney Eskiler G, Ozturk M (2022) Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor talazoparib combination in BRCA-deficient triple negative breast cancer cells. Cell Signal 91:110229","DOI":"10.1016\/j.cellsig.2021.110229"},{"key":"2375_CR12","doi-asserted-by":"crossref","unstructured":"Guney Eskiler G, Cecener G, Egeli U, Tunca B (2018) Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS 126(5):371\u2013379","DOI":"10.1111\/apm.12836"},{"key":"2375_CR13","doi-asserted-by":"crossref","unstructured":"Guney Eskiler G, Yanar S, Akpinar G, Kasap M (2021) Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells. J Biochem Mol Toxicol 35(3):e22678","DOI":"10.1002\/jbt.22678"},{"issue":"6","key":"2375_CR14","first-page":"3574","volume":"38","author":"Y Han","year":"2017","unstructured":"Han Y, Zhang L, Wang W, Li J, Song M (2017) Livin promotes the progression and metastasis of breast cancer through the regulation of epithelial-mesenchymal transition via the p38\/GSK3\u03b2 pathway. Oncol Rep 38(6):3574\u20133582","journal-title":"Oncol Rep"},{"issue":"6","key":"2375_CR15","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/cas.14419","volume":"111","author":"H Hino","year":"2020","unstructured":"Hino H, Iriyama N, Kokuba H, Kazama H, Moriya S, Takano N, Hiramoto M, Aizawa S, Miyazawa K (2020) Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes. Cancer Sci 111(6):2132\u20132145","journal-title":"Cancer Sci"},{"key":"2375_CR16","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.2147\/CMAR.S310649","volume":"13","author":"Y Hu","year":"2021","unstructured":"Hu Y, Gao J, Wang M, Li M (2021) Potential prospect of CDK4\/6 inhibitors in triple-negative breast cancer. Cancer Manag Res 13:5223","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2375_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01597-x","volume":"20","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wu H, Li X (2020) Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. Cancer Cell Int 20(1):1\u201314","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2375_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12885-017-3627-4","volume":"17","author":"AR Hussain","year":"2017","unstructured":"Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, Qadri Z, Ajarim D, Al-Dayel F, Beg S, Al-Kuraya KS (2017) XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer 17(1):640","journal-title":"BMC Cancer"},{"issue":"39","key":"2375_CR19","doi-asserted-by":"publisher","first-page":"25545","DOI":"10.18632\/oncotarget.25370","volume":"9","author":"T Inao","year":"2018","unstructured":"Inao T, Iida Y, Moritani T, Okimoto T, Tanino R, Kotani H, Harada M (2018) Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Oncotarget 9(39):25545","journal-title":"Oncotarget"},{"issue":"5","key":"2375_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/jpm11050340","volume":"11","author":"FG Klein","year":"2021","unstructured":"Klein FG, Granier C, Zhao Y, Pan Q, Tong Z, Gschwend JE, Holm PS, Nawroth R (2021) Combination of talazoparib and palbociclib as a potent treatment strategy in bladder cancer. J Pers Med 11(5):340","journal-title":"J Pers Med"},{"issue":"3","key":"2375_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10549-021-06127-5","volume":"186","author":"L Lanceta","year":"2021","unstructured":"Lanceta L, Lypova N, O\u2019Neill C, Li X, Rouchka E, Chesney J, Imbert-Fernandez Y (2021) Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq. Breast Cancer Res Treat 186(3):677\u2013686","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2375_CR22","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1080\/21691401.2019.1670670","volume":"47","author":"T Li","year":"2019","unstructured":"Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y (2019) Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4\/6-cyclin D-Rb-E2F pathway. Artif Cells Nanomed Biotechnol 47(1):4001\u20134011","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"1","key":"2375_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J (2020a) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19(1):1\u201316","journal-title":"Mol Cancer"},{"issue":"4","key":"2375_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2408-1","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Zhang Y, Wang N, Guo R, Liu Q, Lv C, Wang L, Yang QK (2020b) Pan-cancer analysis reveals synergistic effects of CDK4\/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Cell Death Dis 11(4):1\u201316","journal-title":"Cell Death Dis"},{"key":"2375_CR25","doi-asserted-by":"publisher","first-page":"175883591881834","DOI":"10.1177\/1758835918818346","volume":"10","author":"A Matutino","year":"2018","unstructured":"Matutino A, Amaro C, Verma S (2018) CDK4\/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Ther Adv Med Oncol 10:1758835918818346","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2375_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GCO.0000000000000671","volume":"33","author":"KE McCann","year":"2021","unstructured":"McCann KE, Hurvitz SA (2021) Innovations in targeted therapies for triple negative breast cancer. Curr Opin Obstet Gynecol 33(1):34\u201347","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"2375_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-019-0651-4","volume":"20","author":"CG Murphy","year":"2019","unstructured":"Murphy CG (2019) The role of CDK4\/6 inhibitors in breast cancer. Curr Treat Options Oncol 20(6):1\u201313","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"2375_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1158\/1535-7163.MCT-17-0290","volume":"17","author":"N O'Brien","year":"2018","unstructured":"O\u2019Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Nulty AM, Marchal C, Kalous O, Euw E, Hurvitz S, Mockbee C, Slamon DJ (2018) Preclinical activity of abemaciclib alone or in combination with antimitotic and targeted therapies in breast cancer. Mol Cancer Ther 17(5):897\u2013907","journal-title":"Mol Cancer Ther"},{"key":"2375_CR29","doi-asserted-by":"crossref","unstructured":"Ozman Z, Guney Eskiler G, Sekeroglu MR (2021) In vitro therapeutic effects of abemaciclib on triple-negative breast cancer cells. J Biochem Mol Toxicol 35(9):e22858","DOI":"10.1002\/jbt.22858"},{"issue":"1","key":"2375_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-0160-4","volume":"6","author":"JM Patel","year":"2020","unstructured":"Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Tung N (2020) Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer 6(1):1\u20136","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2375_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/ijms14010411","volume":"14","author":"V Pileczki","year":"2013","unstructured":"Pileczki V, Braicu C, Gherman CD, Berindan-Neagoe I (2013) TNF-\u03b1 gene knockout in triple negative breast cancer cell line induces apoptosis. Int J Mol Sci 14(1):411\u2013420","journal-title":"Int J Mol Sci"},{"key":"2375_CR32","doi-asserted-by":"publisher","unstructured":"Saleh L, Wilson C, Holen I (2021) CDK4\/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. Med Comm 2(4):514\u2013530. https:\/\/doi.org\/10.1002\/mco2.97","DOI":"10.1002\/mco2.97"},{"key":"2375_CR33","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/biomedicines9111512","volume":"9","author":"DD Singh","year":"2021","unstructured":"Singh DD, Parveen A, Yadav DK (2021) Role of PARP in TNBC: mechanism of inhibition, clinical applications and resistance. Biomedicines 9:1512","journal-title":"Biomedicines"},{"key":"2375_CR34","doi-asserted-by":"publisher","first-page":"102255","DOI":"10.1016\/j.ctrv.2021.102255","volume":"99","author":"H Vanacker","year":"2021","unstructured":"Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, Ray-Coquard I (2021) PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations. Cancer Treat Rev 99:102255","journal-title":"Cancer Treat Rev"},{"key":"2375_CR35","first-page":"188590","volume":"2","author":"R Wang","year":"1876","unstructured":"Wang R, Xu K, Gao F, Huang J (1876) Guan X (2021) Clinical considerations of CDK4\/6 inhibitors in triple-negative breast cancer. Biochim Biophys Acta (BBA)-Rev Cancer 2:188590","journal-title":"Biochim Biophys Acta (BBA)-Rev Cancer"},{"issue":"3","key":"2375_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-018-05104-9","volume":"174","author":"T Yamamoto","year":"2019","unstructured":"Yamamoto T, Kanaya N, Somlo G, Chen S (2019) Synergistic anti-cancer activity of CDK4\/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. Breast Cancer Res Treat 174(3):615\u2013625","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2375_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","volume":"40","author":"X Zhu","year":"2021","unstructured":"Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, Jiang Y, Shao Z, Wang Z (2021) Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res 40(1):122","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-022-02375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-022-02375-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-022-02375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T10:07:15Z","timestamp":1680775635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-022-02375-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1007\/s00210-022-02375-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}